| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 10g |
|
||
| Other Sizes |
Purity: =85.0%
| Targets |
Glycol chitosan does not have a specific molecular target but functions as a biocompatible polymer carrier. It enhances membrane permeability and leakage in plant cells such as Glycine max Harosoy 63W. It also exhibits antibacterial activity against various bacterial strains.
|
|---|---|
| ln Vitro |
Through physical encapsulation or chemical conjugation, glycolic chitosan derivatives have been successfully employed to deliver antibacterial and anticancer medicines, including chemical medications, genes, and photosensitizers (PS). Amphiphilic chemicals, which can also form nanoparticles (NPs) for drug administration and cell imaging, can be directly connected to hydrophobic medicines by glycolic chitosan. The excellent tumor homing ability of glycol chitosan nanoparticles based on the enhanced permeability and retention (EPR) effect, low cytotoxicity, ease of chemical modification, good biocompatibility, and biodegradability are just a few benefits of using glycol chitosan derivatives for cell imaging and drug delivery [1]. It has been demonstrated that hydrophobic modifications of glycol chitosan, such as deoxycholic acid-ethylene glycol chitosan and glycol chitosan containing a 5β-cholanic acid moiety, may self-assemble into nanoparticles, which make them promising carriers for hydrophobic genes and medicines [2].
Glycol chitosan inhibits the growth of Escherichia coli, Staphylococcus aureus, and Enterococcus seriolicida with MIC values of 4 μg/mL, 32 μg/mL, and <0.5 μg/mL, respectively. It significantly enhances membrane permeability in Glycine max Harosoy 63W cells. Glycol chitosan derivatives have been successfully used to deliver antimicrobial and anticancer agents. |
| ln Vivo |
In vivo studies demonstrate that glycol chitosan-based nanoparticles achieve 1.5-fold higher tumor accumulation compared to physically loaded particles, indicating enhanced drug delivery efficiency. The polymer exhibits prolonged blood circulation and improved tumor targeting when formulated as nanoparticles.
|
| Enzyme Assay |
Cell membrane permeability assays are performed using plant cells such as Glycine max Harosoy 63W. Cells are treated with glycol chitosan, and membrane permeability and leakage are measured to assess the compound's effect on cellular membranes. Antibacterial activity is evaluated using standard MIC determination methods against bacterial strains.
|
| Cell Assay |
Cytotoxicity assays are conducted in B16F10 cells to evaluate the safety profile of glycol chitosan. The compound shows significantly lower cytotoxicity than chitosan hydrochloride, with an IC50 of 0.21 mg/mL in B16F10 cells. These assays confirm the biocompatibility of the polymer for biomedical applications.
|
| Animal Protocol |
In vivo pharmacokinetic and biodistribution studies are performed in animal models using glycol chitosan-based nanoparticles. The nanoparticles demonstrate prolonged blood circulation and enhanced tumor accumulation (1.5-fold higher vs. physically loaded particles). These studies are essential for evaluating the polymer's potential as a drug delivery vehicle.
|
| ADME/Pharmacokinetics |
Glycol chitosan exhibits favorable pharmacokinetic properties as a drug delivery carrier. Its water solubility across all pH ranges enables stable nanoparticle fabrication and prolonged blood circulation. The polymer's biodegradability ensures eventual clearance from the body, making it suitable for biomedical applications.
|
| Toxicity/Toxicokinetics |
Glycol chitosan demonstrates significantly lower cytotoxicity than chitosan hydrochloride (IC50 0.21 mg/mL in B16F10 cells), indicating a favorable safety profile. Its biocompatibility and biodegradability further support its use in pharmaceutical and biomedical research.
|
| References |
|
| Additional Infomation |
Glycol chitosan is widely used in drug delivery, nanomedicine, and photodynamic therapy research. It has been successfully employed to deliver antibacterial and anticancer drugs, including chemotherapeutics, genes, and photosensitizers. The polymer's favorable properties make it a versatile platform for biomedical applications.
|
| Molecular Formula |
C20H37N3O13
|
|---|---|
| Molecular Weight |
527.52008
|
| CAS # |
123938-86-3
|
| Appearance |
White to off-white solid powder
|
| SMILES |
CC(NC1COC(CO)C(OC2OC(CO)C(OC3OC(CO)C(O)C(O)C3N)C(O)C2N)C1O)=O
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~0.60 mM)
H2O : ~7.5 mg/mL (~0.09 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (0.03 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (0.03 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: 50 mg/mL (0.60 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8957 mL | 9.4783 mL | 18.9566 mL | |
| 5 mM | 0.3791 mL | 1.8957 mL | 3.7913 mL | |
| 10 mM | 0.1896 mL | 0.9478 mL | 1.8957 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA